急性冠脉综合征住院患者血红蛋白下降的预后意义
基于MATRIX试验中7781例接受有创治疗的ACS患者,83.6%出现院内血红蛋白下降,其中88.5%无显性出血。无显性出血者中,血红蛋白下降≥3 g/dl与1年死亡率独立相关(minor HR 2.37,95%CI 1.32-4.24,p=0.004)。
要点
- ACS有创治疗患者中院内血红蛋白下降常见,多数无显性出血。
- 无显性出血时血红蛋白下降≥3 g/dl仍与1年死亡率升高独立相关。
- 显性出血者血红蛋白下降与死亡关联方向相似但置信区间更宽。
核心结论
- ACS有创治疗患者院内血红蛋白下降≥3 g/dl,即使无显性出血,也独立增加1年死亡风险。
研究设计与样本
- MATRIX试验事后分析,纳入7781例随机化后24小时存活且有血红蛋白数据的ACS患者。
- 按基线至最低血红蛋白下降幅度分为minimal(<3 g/dl)、minor(≥3且<5 g/dl)、major(≥5 g/dl)。
- 进一步按有无裁定院内显性出血分层,用多变量Cox回归分析血红蛋白下降与死亡关联。
主要发现
- 6504例(83.6%)出现血红蛋白下降,其中5756例(88.5%)无显性出血,748例(11.5%)有显性出血。
- 无显性出血者中,minor下降与1年死亡率独立相关(HR 2.37,95%CI 1.32-4.24,p=0.004)。
- 无显性出血者中,major下降与1年死亡率关联(HR 2.58,95%CI 0.98-6.78,p=0.054)。
- 有显性出血者中,minor下降HR 3.53(95%CI 1.06-11.79),major下降HR 13.32(95%CI 3.01-58.98)。
临床怎么用
- ACS有创治疗患者应监测血红蛋白变化,即使无显性出血,下降≥3 g/dl也提示1年死亡风险升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Contemporary definitions of bleeding endpoints are restricted mostly to clinically overt events. Whether hemoglobin drop per se, with or without overt bleeding, adversely affects the prognosis of patients with acute coronary syndrome (ACS) remains unclear. OBJECTIVES: The aim of this study was to examine in the MATRIX (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox) trial the incidence, predictors, and prognostic implications of in-hospital hemoglobin drop in patients with ACS managed invasively stratified by the presence of in-hospital bleeding. METHODS: Patients were categorized by the presence and amount of in-hospital hemoglobin drop on the basis of baseline and nadir hemoglobin values and further stratified by the occurrence of adjudicated in-hospital bleeding. Hemoglobin drop was defined as minimal (<3 g/dl), minor (≥3 and <5 g/dl), or major (≥5 g/dl). Using multivariate Cox regression, we modeled the association between hemoglobin drop and mortality in patients with and without overt bleeding. RESULTS: Among 7,781 patients alive 24 h after randomization with available hemoglobin data, 6,504 patients (83.6%) had hemoglobin drop, of whom 5,756 (88.5%) did not have overt bleeding and 748 (11.5%) had overt bleeding. Among patients without overt bleeding, minor (hazard ratio [HR]: 2.37; 95% confidence interval [CI]: 1.32 to 4.24; p = 0.004) and major (HR: 2.58; 95% CI: 0.98 to 6.78; p = 0.054) hemoglobin drop were independently associated with higher 1-year mortality. Among patients with overt bleeding, the association of minor and major hemoglobin drop with 1-year mortality was directionally similar but had wider CIs (minor: HR: 3.53 [95% CI: 1.06 to 11.79]; major: HR: 13.32 [95% CI: 3.01 to 58.98]). CONCLUSIONS: Among patients with ACS managed invasively, in-hospital hemoglobin drop ≥3 g/dl, even in the absence of overt bleeding, is common and is independently associated with increased risk for 1-year mortality. (Minimizing Adverse Haemorrhagic Events by Transradial Access Site and Systemic Implementation of Angiox; NCT01433627).
引用
- Leonardi S, Gragnano F, Carrara G, et al. Prognostic Implications of Declining Hemoglobin Content in Patients Hospitalized With Acute Coronary Syndromes. J Am Coll Cardiol. 2021. PMID: 33509394. doi:10.1016/j.jacc.2020.11.046
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。